Journal
SURGICAL CLINICS OF NORTH AMERICA
Volume 98, Issue 1, Pages 95-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.suc.2017.09.009
Keywords
Resectable pancreatic cancer; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Adjuvant therapy; Neoadjuvant therapy; Preoperative therapy; Chemotherapy; Resection
Categories
Ask authors/readers for more resources
Since the advent of modern surgery for pancreatic cancer, clinicians have recognized this cancer's propensity to recur locally, metastasize, and cause death. Despite significant efforts to improve patient outcomes with better adjuvant therapy, only modest gains in survival have been observed. An alternative strategy of neoadjuvant therapy followed by surgery has the potential to improve patient selection and survival and expand the pool of patients eligible for curative surgery. This article summarizes large, randomized trials of adjuvant therapy, explains the limitations imposed by up-front surgery, and suggests neoadjuvant therapy as a rational alternative to initial surgery and adjuvant therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available